These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1892775)

  • 1. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
    Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
    Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
    Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
    Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
    O'Brien ME; Nicolson M; Montes A; Tidy A; Ashley S; Powles TJ
    Br J Cancer; 1994 Nov; 70(5):980-3. PubMed ID: 7524607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.
    Stein RC; Bower M; Law M; Bliss JM; Barton C; Gazet JC; Ford HT; Coombes RC
    Eur J Cancer; 1992; 28A(12):1963-5. PubMed ID: 1419290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelosuppression after methotrexate, mitozantrone, and mitomycin C for treatment of advanced breast cancer.
    Marks A; Goodman A; Dougherty S; Ashford R
    Lancet; 1987 Apr; 1(8538):915. PubMed ID: 2882308
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
    Gregory RK; Powles TJ; Chang JC; Ashley S
    Eur J Cancer; 1997 Nov; 33(13):2194-7. PubMed ID: 9470805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
    Gundersen S; Kvinnsland S; Klepp O; Kvaløy S; Lund E; Høst H
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1431-4. PubMed ID: 3595668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine.
    Green JA; Slater AJ; Campbell IR; Kelly V
    Breast Cancer Res Treat; 1996; 39(2):155-63. PubMed ID: 8872324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Tada A; Ueno K; Yamazaki H; Nakamura T; Ito Y; Inagaki J
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):327-32. PubMed ID: 2494947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy using the CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil) and the VAC protocol (vincristine, adriamycin and cyclophosphamide) in patients with advanced breast cancer].
    Glińska H; Zulichowska J; Radziszewska J; Sukiennik-Siuda M; Trabka E
    Nowotwory; 1987; 37(3):251-61. PubMed ID: 3438177
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.
    Panasci L; Shenouda G; Begin L; Pollak M; Reinke A; Margolese R
    Cancer Chemother Pharmacol; 1990; 26(6):457-60. PubMed ID: 2121379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study.
    Pedrazzoli P; Zamagni C; Martoni A; Capotorto AM; Da Prada GA; Pavesi L; Preti P; Lelli G; Pannuti F; Robustelli della Cuna G
    Tumori; 1994 Aug; 80(4):273-5. PubMed ID: 7526508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
    Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
    Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
    Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
    J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: a randomized study comparing different times and routes of administration of Corynebacterium parvum.
    Fritze D; Massner B; Becher R; Kaufmann M; Illiger HJ; Hartlapp J; Queisser W; Abel U; Edler L; Mayr AC
    Klin Wochenschr; 1984 Feb; 62(4):162-7. PubMed ID: 6368960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
    Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.